Cancer Research and Treatment

Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; www.thetcr.org) is an Open Access, peer-reviewed journal, published by AME Publishing Company, publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. TCR will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving cancer patients lives. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles. The Official Publication of Society for Translational Cancer Research (STCR),Hong Kong

《癌症研究与治疗》是韩国癌症协会的一份同行评审的开放访问出版物。每季度出版一期，每年出版一册。简称为癌症治疗。它接受与实验和临床癌症研究相关的手稿。受试者包括致癌、肿瘤生物学、分子肿瘤学、癌症遗传学、肿瘤免疫学、流行病学、预测标志物和癌症预防、病理学、癌症诊断、筛查和治疗，包括化疗、手术、放射治疗、免疫治疗、基因治疗、多模态治疗和姑息治疗。癌症研究与治疗（CRT）由SCI、MEDLine、PubMed、PubMed Central、Koreamed、CrossRef、Chemical Abstracts Service（CAS）、Scopus、Komci和Google Scholar编制索引/跟踪/覆盖。